Key result
CPAP during sleep reduces systolic LV transmural pressure by ~20 mm Hg in CHF with OSA.
Why the study?
Chronic nightly CPAP abolishes OSA and improves LVEF in CHF patients, and lowering LV afterload during sleep was hypothesized as an underlying mechanism.
Does continuous positive airway pressure (CPAP) reduce blood pressure and left ventricular afterload (systolic left ventricular transmural pressure) during sleep in pharmacologically treated congestive heart failure patients with obstructive sleep apnea?
Does continuous positive airway pressure (CPAP) reduce blood pressure and left ventricular afterload (systolic left ventricular transmural pressure) during sleep in pharmacologically treated congestive heart failure patients with obstructive sleep apnea?
CPAP provides a nonpharmacological means of acutely reducing left ventricular afterload and heart rate during sleep in pharmacologically treated heart failure patients with obstructive sleep apnea.
Answers are grounded in this paper and cite their sources.
May acutely reduce afterload in treated HF-OSA; leaves open outcome effects.
BACKGROUND: The objectives of this study were to determine the effects of continuous positive airway pressure (CPAP) on blood pressure (BP) and systolic left ventricular transmural pressure (LVPtm) during sleep in congestive heart failure (CHF) patients with obstructive sleep apnea (OSA). In CHF patients with OSA, chronic nightly CPAP treatment abolishes OSA and improves left ventricular (LV) ejection fraction. We hypothesized that one mechanism whereby CPAP improves cardiac function in CHF patients with OSA is by lowering LV afterload during sleep. METHODS AND RESULTS: Eight pharmacologically treated CHF patients with OSA were studied during overnight polysomnography. BP and esophageal pressure (Pes) (ie, intrathoracic pressure) were recorded before the onset of sleep and during stage 2 non-rapid eye movement sleep before, during, and after CPAP application. OSA was associated with an increase in systolic BP (from 120.4+/-7.8 to 131.8+/-10.6 mm Hg, P<0.05) and systolic LVPtm (from 124.4+/-7.7 to 137.2+/-10.8 mm Hg, P<0.05) from wakefulness to stage 2 sleep. CPAP alleviated OSA, improved oxyhemoglobin saturation, and reduced systolic BP in stage 2 sleep to 115.4+/-8.5 mm Hg (P<0.01), systolic LVPtm to 117.4+/-8.5 mm Hg (P<0.01), heart rate, Pes amplitude, and respiratory rate. CONCLUSIONS: In CHF patients with OSA, LV afterload increases from wakefulness to stage 2 sleep. By alleviating OSA, CPAP reduces LV afterload and heart rate, unloads inspiratory muscles, and improves arterial oxygenation during stage 2 sleep. CPAP is a nonpharmacological means of further reducing afterload and heart rate during sleep in pharmacologically treated CHF patients with OSA.
No takes yet. Share an insight, caveat, or question.
Tkáčová et al. (1998) studied Congestive heart failure with obstructive sleep apnea (n=8). Continuous positive airway pressure (CPAP) vs. Stage 2 non-rapid eye movement sleep before and after CPAP application was evaluated on Systolic blood pressure and systolic left ventricular transmural pressure during stage 2 non-rapid eye movement sleep (p=<0.01). CPAP during stage 2 sleep reduced systolic BP and systolic LV transmural pressure in CHF patients with OSA.
Synapse has enriched 10 related papers. Consider them for comparative context: